Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1992 Feb 1;175(2):405–413. doi: 10.1084/jem.175.2.405

Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease

PMCID: PMC2119110  PMID: 1732411

Abstract

In this report we have investigated macrophage (M phi) activity and tumor necrosis factor alpha (TNF-alpha) production during graft-vs.- host disease (GVHD). TNF-alpha production by M phi requires two signals: priming of M phi by interferon followed by triggering of TNF- alpha production and release by lipopolysaccharide (LPS). The state of M phi activation was examined in nonirradiated B6AF1 recipient mice injected with either 60 x 10(6) (acute GVHD) or 30 x 10(6) (nonlethal GVHD) parental B6 lymphoid cells. During the early phase of acute GVHD, administration of normally sublethal amounts of LPS-triggered release of significant amounts of TNF-alpha into the serum resulting in death of the animals within 36 h. Normal animals treated with the same dose of LPS neither died nor produced detectable amounts of serum TNF-alpha. In vitro studies demonstrated that M phi were primed during GVHD. The level of M phi priming was greater during acute GVHD than nonlethal GVHD since 100-fold less LPS was required to trigger killing of a TNF- alpha-sensitive cell line by M phi from acute GVHD animals. The amount of TNF-alpha released into the serum after LPS injection increased during the course of the GVHD and was significantly greater in acute GVH-reactive mice. Endogenous LPS was detected in the serum of acute GVH-reactive animals coincident with the onset of mortality. The data provide evidence that during GVHD M phi are primed as a result of the allogeneic reaction and that endogenous LPS therefore triggers M phi production of TNF-alpha resulting in the symptoms characteristic of acute GVHD.

Full Text

The Full Text of this article is available as a PDF (895.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BILLINGHAM R. E., BRENT L. A simple method for inducing tolerance of skin homografts in mice. Transplant Bull. 1957 Apr;4(2):67–71. [PubMed] [Google Scholar]
  2. BLAESE R. M., MARTINEZ C., GOOD R. A. IMMUNOLOGIC INCOMPETENCE OF IMMUNOLOGICALLY RUNTED ANIMALS. J Exp Med. 1964 Feb 1;119:211–224. doi: 10.1084/jem.119.2.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beutler B. A., Milsark I. W., Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985 Dec;135(6):3972–3977. [PubMed] [Google Scholar]
  4. Beutler B., Mahoney J., Le Trang N., Pekala P., Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985 May 1;161(5):984–995. doi: 10.1084/jem.161.5.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  6. Beutler B., Tkacenko V., Milsark I., Krochin N., Cerami A. Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype. J Exp Med. 1986 Nov 1;164(5):1791–1796. doi: 10.1084/jem.164.5.1791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cerami A., Ikeda Y., Le Trang N., Hotez P. J., Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett. 1985;11(3-4):173–177. doi: 10.1016/0165-2478(85)90165-8. [DOI] [PubMed] [Google Scholar]
  8. Charley M. R., Mikhael A., Bennett M., Gilliam J. N., Sontheimer R. D. Prevention of lethal, minor-determinate graft-host disease in mice by the in vivo administration of anti-asialo GM1. J Immunol. 1983 Nov;131(5):2101–2103. [PubMed] [Google Scholar]
  9. Cunningham A. J., Szenberg A. Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology. 1968 Apr;14(4):599–600. [PMC free article] [PubMed] [Google Scholar]
  10. Cuturi M. C., Murphy M., Costa-Giomi M. P., Weinmann R., Perussia B., Trinchieri G. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med. 1987 Jun 1;165(6):1581–1594. doi: 10.1084/jem.165.6.1581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Djeu J. Y., Blanchard D. K., Halkias D., Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol. 1986 Nov 1;137(9):2980–2984. [PubMed] [Google Scholar]
  12. Elie R., Lapp W. S. Graft versus host-induced immunosuppression: mechanism of depressed T-cell helper function in vitro. Cell Immunol. 1977 Nov;34(1):38–48. doi: 10.1016/0008-8749(77)90227-1. [DOI] [PubMed] [Google Scholar]
  13. Flick D. A., Gifford G. E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984 Mar 30;68(1-2):167–175. doi: 10.1016/0022-1759(84)90147-9. [DOI] [PubMed] [Google Scholar]
  14. GORER P. A., BOYSE E. A. Pathological changes in F1 hybrid mice following transplantation of spleen cells from donors of the parental strains. Immunology. 1959 Apr;2(2):182–193. [PMC free article] [PubMed] [Google Scholar]
  15. Ghayur T., Seemayer T. A., Kongshavn P. A., Gartner J. G., Lapp W. S. Graft-versus-host reactions in the beige mouse. An investigation of the role of host and donor natural killer cells in the pathogenesis of graft-versus-host disease. Transplantation. 1987 Aug;44(2):261–267. doi: 10.1097/00007890-198708000-00017. [DOI] [PubMed] [Google Scholar]
  16. Ghayur T., Seemayer T. A., Lapp W. S. Prevention of murine graft-versus-host disease by inducing and eliminating ASGM1+ cells of donor origin. Transplantation. 1988 Mar;45(3):586–590. doi: 10.1097/00007890-198803000-00017. [DOI] [PubMed] [Google Scholar]
  17. Ghayur T., Xenocostas A., Seemayer T. A., Lapp W. S. Induction, specificity and elimination of asialo-GM1+ graft-versus-host effector cells of donor origin. Scand J Immunol. 1991 Oct;34(4):497–508. doi: 10.1111/j.1365-3083.1991.tb01573.x. [DOI] [PubMed] [Google Scholar]
  18. Gifford G. E., Lohmann-Matthes M. L. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J Natl Cancer Inst. 1987 Jan;78(1):121–124. doi: 10.1093/jnci/78.1.121. [DOI] [PubMed] [Google Scholar]
  19. Gordon J. R., Galli S. J. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature. 1990 Jul 19;346(6281):274–276. doi: 10.1038/346274a0. [DOI] [PubMed] [Google Scholar]
  20. HOWARD J. G. Increased sensitivity to bacterial endotoxin of F-1 hybrid mice undergoing graft-versus-host reaction. Nature. 1961 Jun 17;190:1122–1122. doi: 10.1038/1901122a0. [DOI] [PubMed] [Google Scholar]
  21. HOWARD J. Changes in the activity of the reticulo-endothelial system (RES) following the injection of parental spleen cells into F1 hybrid mice. Br J Exp Pathol. 1961 Feb;42:72–82. [PMC free article] [PubMed] [Google Scholar]
  22. Hampton R. Y., Golenbock D. T., Penman M., Krieger M., Raetz C. R. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature. 1991 Jul 25;352(6333):342–344. doi: 10.1038/352342a0. [DOI] [PubMed] [Google Scholar]
  23. Havell E. A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol. 1989 Nov 1;143(9):2894–2899. [PubMed] [Google Scholar]
  24. Hirokawa M., Takatsu H., Niitsu H., Nishinari T., Nimura T., Itoh T., Chubachi A., Miura I., Yoshida K., Endo Y. Serum tumor necrosis factor-alpha levels in allogeneic bone marrow transplant recipients with acute leukemia. Tohoku J Exp Med. 1989 Nov;159(3):237–244. doi: 10.1620/tjem.159.237. [DOI] [PubMed] [Google Scholar]
  25. Holler E., Kolb H. J., Möller A., Kempeni J., Liesenfeld S., Pechumer H., Lehmacher W., Ruckdeschel G., Gleixner B., Riedner C. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990 Feb 15;75(4):1011–1016. [PubMed] [Google Scholar]
  26. Jones J. M., Wilson R., Bealmear P. M. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res. 1971 Mar;45(3):577–588. [PubMed] [Google Scholar]
  27. Klimpel G. R., Annable C. R., Cleveland M. G., Jerrells T. R., Patterson J. C. Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN-gamma production. J Immunol. 1990 Jan 1;144(1):84–93. [PubMed] [Google Scholar]
  28. Lapp W. S., Ghayur T., Mendes M., Seddik M., Seemayer T. A. The functional and histological basis for graft-versus-host-induced immunosuppression. Immunol Rev. 1985 Dec;88:107–133. doi: 10.1111/j.1600-065x.1985.tb01155.x. [DOI] [PubMed] [Google Scholar]
  29. Lapp W. S., Möller G. Prolonged survival of H-2 incompatible skin allografts on F1 animals treated with parental lymphoid cells. Immunology. 1969 Sep;17(3):339–344. [PMC free article] [PubMed] [Google Scholar]
  30. McGarrity G. J., Carson D. A. Adenosine phosphorylase-mediated nucleoside toxicity. Application towards the detection of mycoplasmal infection in mammalian cell cultures. Exp Cell Res. 1982 May;139(1):199–205. doi: 10.1016/0014-4827(82)90333-0. [DOI] [PubMed] [Google Scholar]
  31. Mestan J., Digel W., Mittnacht S., Hillen H., Blohm D., Möller A., Jacobsen H., Kirchner H. Antiviral effects of recombinant tumour necrosis factor in vitro. 1986 Oct 30-Nov 5Nature. 323(6091):816–819. doi: 10.1038/323816a0. [DOI] [PubMed] [Google Scholar]
  32. Moore R. H., Lampert I. A., Chia Y., Aber V. R., Cohen J. Effect of immunization with Escherichia coli J5 on graft-versus-host disease induced by minor histocompatibility antigens in mice. Transplantation. 1987 Aug;44(2):249–253. doi: 10.1097/00007890-198708000-00015. [DOI] [PubMed] [Google Scholar]
  33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  34. Mowat A. M. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology. 1989 Sep;68(1):18–23. [PMC free article] [PubMed] [Google Scholar]
  35. Munford R. S., Hall C. L., Lipton J. M., Dietschy J. M. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest. 1982 Oct;70(4):877–888. doi: 10.1172/JCI110684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Männel D. N., Moore R. N., Mergenhagen S. E. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun. 1980 Nov;30(2):523–530. doi: 10.1128/iai.30.2.523-530.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Niederwieser D., Herold M., Woloszczuk W., Aulitzky W., Meister B., Tilg H., Gastl G., Bowden R., Huber C. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation. 1990 Oct;50(4):620–625. doi: 10.1097/00007890-199010000-00019. [DOI] [PubMed] [Google Scholar]
  38. Owens W. E., Berg R. D. Bacterial translocation from the gastrointestinal tract of athymic (nu/nu) mice. Infect Immun. 1980 Feb;27(2):461–467. doi: 10.1128/iai.27.2.461-467.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Pace J. L., Russell S. W. Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J Immunol. 1981 May;126(5):1863–1867. [PubMed] [Google Scholar]
  40. Pace J. L., Russell S. W., LeBlanc P. A., Murasko D. M. Comparative effects of various classes of mouse interferons on macrophage activation for tumor cell killing. J Immunol. 1985 Feb;134(2):977–981. [PubMed] [Google Scholar]
  41. Pace J. L., Russell S. W., Torres B. A., Johnson H. M., Gray P. W. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol. 1983 May;130(5):2011–2013. [PubMed] [Google Scholar]
  42. Papadimitriou J. M., Keast D. The electron microscopy of livers of mice runted as a result of the graft versus host reaction and bacterial endotoxin. Br J Exp Pathol. 1969 Dec;50(6):574–577. [PMC free article] [PubMed] [Google Scholar]
  43. Parthenais E., Lapp W. S. Evidence for two types of non-specific suppressor cells activated by the graft-versus-host reaction in mice. Scand J Immunol. 1978 Mar;7(3):215–220. doi: 10.1111/j.1365-3083.1978.tb00446.x. [DOI] [PubMed] [Google Scholar]
  44. Peters P. M., Ortaldo J. R., Shalaby M. R., Svedersky L. P., Nedwin G. E., Bringman T. S., Hass P. E., Aggarwal B. B., Herberman R. B., Goeddel D. V. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol. 1986 Oct 15;137(8):2592–2598. [PubMed] [Google Scholar]
  45. Piguet P. F., Grau G. E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987 Nov 1;166(5):1280–1289. doi: 10.1084/jem.166.5.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Reyes V. E., Klimpel G. R. Interferon alpha/beta synthesis during acute graft-versus-host disease. Transplantation. 1987 Mar;43(3):412–416. doi: 10.1097/00007890-198703000-00018. [DOI] [PubMed] [Google Scholar]
  47. Sandvig S., Laskay T., Andersson J., De Ley M., Andersson U. Gamma-interferon is produced by CD3+ and CD3- lymphocytes. Immunol Rev. 1987 Jun;97:51–65. doi: 10.1111/j.1600-065x.1987.tb00516.x. [DOI] [PubMed] [Google Scholar]
  48. Schumann R. R., Leong S. R., Flaggs G. W., Gray P. W., Wright S. D., Mathison J. C., Tobias P. S., Ulevitch R. J. Structure and function of lipopolysaccharide binding protein. Science. 1990 Sep 21;249(4975):1429–1431. doi: 10.1126/science.2402637. [DOI] [PubMed] [Google Scholar]
  49. Seemayer T. A., Lapp W. S., Bolande R. P. Thymic involution in murine graft-versus-host reaction. Epithelial injury mimicking human thymic dysplasia. Am J Pathol. 1977 Jul;88(1):119–134. [PMC free article] [PubMed] [Google Scholar]
  50. Sherry B. A., Gelin J., Fong Y., Marano M., Wei H., Cerami A., Lowry S. F., Lundholm K. G., Moldawer L. L. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 1989 Jun;3(8):1956–1962. doi: 10.1096/fasebj.3.8.2721856. [DOI] [PubMed] [Google Scholar]
  51. Storb R., Prentice R. L., Buckner C. D., Clift R. A., Appelbaum F., Deeg J., Doney K., Hansen J. A., Mason M., Sanders J. E. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983 Feb 10;308(6):302–307. doi: 10.1056/NEJM198302103080602. [DOI] [PubMed] [Google Scholar]
  52. Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985 Nov 22;230(4728):943–945. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  53. Symington F. W., Pepe M. S., Chen A. B., Deliganis A. Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation. 1990 Sep;50(3):518–521. doi: 10.1097/00007890-199009000-00033. [DOI] [PubMed] [Google Scholar]
  54. Torti F. M., Dieckmann B., Beutler B., Cerami A., Ringold G. M. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science. 1985 Aug 30;229(4716):867–869. doi: 10.1126/science.3839597. [DOI] [PubMed] [Google Scholar]
  55. Tracey K. J., Wei H., Manogue K. R., Fong Y., Hesse D. G., Nguyen H. T., Kuo G. C., Beutler B., Cotran R. S., Cerami A. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988 Mar 1;167(3):1211–1227. doi: 10.1084/jem.167.3.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Velardi A., Varese P., Terenzi A., Dembech C., Albi N., Grossi C. E., Moretta L., Martelli M. F., Grignani F., Mingari M. C. Lymphokine production by T-cell clones after human bone marrow transplantation. Blood. 1989 Oct;74(5):1665–1672. [PubMed] [Google Scholar]
  57. Vlassara H., Brownlee M., Manogue K. R., Dinarello C. A., Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 1988 Jun 10;240(4858):1546–1548. doi: 10.1126/science.3259727. [DOI] [PubMed] [Google Scholar]
  58. Wall D. A., Hamberg S. D., Reynolds D. S., Burakoff S. J., Abbas A. K., Ferrara J. L. Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression. J Immunol. 1988 May 1;140(9):2970–2976. [PubMed] [Google Scholar]
  59. van Bekkum D. W., Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst. 1977 Mar;58(3):787–790. doi: 10.1093/jnci/58.3.787. [DOI] [PubMed] [Google Scholar]
  60. van Bekkum D. W., Roodenburg J., Heidt P. J., van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst. 1974 Feb;52(2):401–404. doi: 10.1093/jnci/52.2.401. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES